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Abstract 
Background: To determine the occurrence of macular edema (ME) in vitreoretinal lymphoma (VRL).
Methods: Retrospective analysis of 17 patients (31 eyes) with VRL. A review of the literature was done as well.
Results: Nine patients (15 eyes) had fluorescein angiography and/or optical coherence tomography at presentation. 
In the ME group (six eyes of four patients), three patients (five eyes) had prior chemotherapy and radiation. Excluding 
eyes with radiation retinopathy (three eyes), rate of ME was 25% (3/12). When two unirradiated fellow eyes of eyes 
with radiation retinopathy were also excluded, ME rate was 10% (1/10). Excluding the eyes with intraocular surgery, 
the rate of ME was 0%. In the group without ME (nine eyes of six patients), one patient (one eye) was treated with 
chemotherapy and radiation and three patients (five eyes) with chemotherapy. Review of the literature showed that 
the ME was found between 2 and 60% of cases, but most of the cases with ME had prior interventions.
Conclusions: Macular edema in VRL is not uncommon but usually related to prior interventions. Macular edema as 
an initial presentation of VRL is rare.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Vitreoretinal lymphoma (VRL) is a rare form of non-
Hodgkin central nervous system lymphoma (CNS-L). 
Malignant diffuse large B cell is the most common form, 
although rarely, a T-cell form occurs as well [1, 2]. These 
cells invade the vitreous and retina, including the subreti-
nal and sub-RPE (retinal pigment epithelium) space.
Ocular involvement can precede (primary VRL), 
occur in tandem with, or follow CNS disease (secondary 
VRL) [3]. Therefore, patients with CNS-L will go on to 
develop ocular involvement 15–25% of the time; while in 
those patients with primary VRL, upwards of 65–90% of 
patients will develop cerebral disease [4, 5]. Occasionally, 
VRL is associated with systemic non-Hodgkin lymphoma 
[6, 7].
VRL usually affects elderly patients between the sixth 
and seventh decades of life but can occasionally occur in 
younger patients, though these patients tend to be immu-
nocompromised. It is bilateral in 60–90% of cases but is 
sometimes asymmetric at the time of presentation [6]. 
Floaters and blurred vision are the most typical symp-
toms. Clinical findings can vary widely, and the condition 
may masquerade as a bilateral posterior uveitis.
The most common presentation is vitreous invasion 
by clumps of cells. Solitary or multifocal sub-RPE lesions 
can occur with or without vitreous involvement. Less 
frequent manifestations include: macular edema (ME), 
iridocyclitis, optic neuropathy, vasculitis, retinal detach-
ment, and retinal hemorrhage [5, 8].
Macular edema is a nonspecific finding of uveitis sec-
ondary to blood-retinal barrier disruption as a result 
of inflammatory mediators. It is frequently present in 
vitreous inflammatory diseases such as intermediate 
uveitis [9], but it is also seen in anterior, posterior, and 
panuveitis; it is the main cause of visual impairment in 
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many cases of uveitis [10, 11]. Interestingly, ME does not 
appear to be a characteristic finding in VRL, though there 
are few studies and some use only funduscopic deter-
mination [12–15]. Fluorescein angiography and ocular 
coherence tomography (OCT) are very good at detect-
ing ME in VRL. The purpose of the present review is to 
determine the occurrence and behavior of ME at the time 
of the initial presentation of VRL.
This is a retrospective study of all patients diagnosed 
with VRL within a 5-year period (January 2005–January 
2010) at Mayo Clinic, Rochester, Minnesota, USA. All 
patients who were included in this study had tissue diag-
nosis at Mayo Clinic within an average of three weeks of 
initial presentation.
After Mayo Clinic IRB approval, we reviewed all cases 
diagnosed with VRL that had tissue confirmation. We 
then selected those that had fluorescein angiography 
(FA) and/or OCT at their initial visit at Mayo. These were 
classified in two groups depending on the presence or 
absence of ME. In both groups, we analyzed the best cor-
rected visual acuity (BCVA) as well as the relevant past 
medical, pharmacological, radiotherapy, and ocular his-
tory, including prior intraocular procedures. Intraocular 
findings, including the severity of vitreous cells and reti-
nal involvement (intraretinal or subretinal) at the time of 
initial examination, were also recorded. Those eyes with 
FA and/or OCT had their charts re-evaluated at 6 and 
12 months’ time.
The OCT was analyzed with careful attention to the 
appearance of intraretinal cysts or fluid, retinal thickness, 
flattening of the foveal depression, decrease of intrareti-
nal reflectivity, and serous retinal detachment as a result 
of fluid accumulation in the OCT in six radial line scan 
images.
Any detectable ME on OCT was classified in three 
groups (i.e., cystoid, diffuse, or serous detachment) as 
described in the literature [16–18]. Briefly, cystoid ME is 
characterized by the presence of low-reflective intrareti-
nal spaces separated by thin retinal tissue. Diffuse ME has 
an increased macular thickness with a spongy appearance 
of the retinal layer. Finally, serous detachment is defined 
as the presence of serous retinal detachment, epiretinal 
membrane, or vitreoretinal traction.
To classify the angiographic ME, we used the grad-
ing system of Yannuzzi et al. [19, 20]. ME was classified 
in two patterns: cystoid or diffuse. The cystoid macular 
pattern demonstrated a demarcated petaloid pattern of 
hyperfluorescence, whereas the diffuse pattern showed 
a late spread of leakage in a poorly demarcated area in 
the foveal or perifoveal region. Grade 0 corresponded 
to the absence of perifoveal hyperfluorescence; grade 
1 referred to incomplete perifoveal hyperfluorescence; 
grade 2 referred to mild 360° hyperfluorescence; grade 
3 was characterized by moderate 360° hyperfluores-
cence with the area of hyperfluorescence being 1 disc 
diameter across; and grade 4 referred to severe 360° 
hyperfluorescence with the hyperfluorescent area hav-
ing a minimal cross-sectional diameter of 1.5 disc 
diameter.
Subsequently, a review of the English literature was 
performed as well. Keywords used included vitreoretinal 
lymphoma and intraocular lymphoma.
Cases at Mayo Clinic
During the 5-year study period, 17 patients (31 eyes) 
were histopathologically diagnosed with VRL, but only 
15 patients required imaging at the first visit. In eight 
patients (47%), VRL preceded the CNS-L; whereas in 
nine patients (53%), VRL occurred in patients with the 
diagnosis of CNS-L. Sixteen (52%) were right eyes and 15 
(48%) were left eyes.
The median age for all 17 patients diagnosed with VRL 
was 66  years (range 54–80  years) at presentation. Nine 
patients (53%) were female and eight (47%) were male 
(Table  1). Fourteen patients (82%) had bilateral presen-
tation and three (18%) had unilateral presentation. Nine 
patients (15 eyes) were imaged with FA and/or OCT at 
the first examination (Fig. 1).
ME group
Six eyes (four patients) had ME by FA and/or OCT at the 
first examination, representing 40% of the imaged VRL 
patients (6 of 15) (Table 2).
The median age in this group was 69  years (range 
57–72  years). Two patients were female (50%) and two 
were male (50%). Two were right eyes (33.3%) and four 
were left eyes (66.7%).
Only one patient had high blood pressure and was on 
medical therapy and none had diabetes mellitus. Four 
eyes had previous intraocular surgery (two had cataract 
surgery, and two had pars plana vitrectomy).
Three patients (75%) had secondary VRL at the time 
of diagnosis of CNS-L; two had prior CNS-L and one 
had diffuse large B-cell lymphoma with CNS involve-
ment diagnosed 3–7 and 11 years prior to their evalua-
tion, respectively. One patient (25%) developed CNS-L 
5 months after our examination (primary VRL).
All three patients with previous CNS-L had been pre-
viously treated with whole-brain radiotherapy (WBRT). 
The radiation details of only one patient (patient 1) were 
known to us because the other patients were treated else-
where. Additionally, all three patients had been treated 
with chemotherapy (CT) before the WBRT. One patient 
(patient 4) had post-radiation CT and was still on a main-
tenance dosage of intravenous methotrexate at the time 
of evaluation.
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Patient 2 had primary VRL and had no prior treat-
ment with CT or WBRT. However, he had undergone 
pars plana vitrectomy (PPV) with intravitreal corticoster-
oid injection and cataract surgery in the left eye, 11 and 
5 months before our examination, respectively.
The clinical presentation was blurred vision (5 of 6) 
and blurred vision plus floaters (1 of 6) for a median of 
3  months (range 1–9). The median BCVA was 20/45 
(range 20/25–20/150). Ophthalmologic signs included: a 
median anterior chamber cell grade of 1+ (range 0–3+), 
a median vitreous cell grade of 3+ (range rare-3+), sub-
retinal infiltrates (2 of 6), intraretinal infiltrates (1 of 6), 
cotton wool spots (2 of 6), intraretinal hemorrhages (1 of 
6), and perimacular hard exudates (1 of 6) (Table 2).
However, mixed lesions in the fundus (i.e. cotton wool 
spots, intraretinal hemorrhages, and hard exudates) were 
found in three patients (3 of 6 eyes) with ME who had 
received WBRT at 8, 36, and 132 months before presen-
tation (Figs. 2, 3). For this reason, we could not rule out 
radiation retinopathy (RR) as an etiology of ME in these 
three eyes. Thus, excluding eyes with RR, the rate of ME 
was 25% (3 of 12). However, two additional eyes were the 
fellow eyes of those with definite RR (in which no signs of 
RR were found). Excluding these as well, the rate of ME 
in eyes with VRL was 10% (1 of 10) (Fig. 3). Looking at it 
differently, of five patients without WBRT, 1 of 9 (11.1%) 
eyes had ME.
Of these three eyes with ME but without signs of RR 
(or which were not fellow eyes of those with RR), one eye 
did not have WBRT but did have a history of PPV and 
cataract surgery history, one had cataract surgery only, 
and one did not have any intraocular procedures before 
our examination. The clinical presentation in these eyes 
was blurred vision (2 of 3) or blurred vision plus float-
ers (1 of 3) for a median of 2  months (range 2–6). The 
median BCVA was 20/50 (20/25–20/150), and ophthal-
mologic signs included a median anterior chamber cell 
grade of 0 (range 0–trace), a median vitreous cell grade 
of 1+ (range rare-3+), and intraretinal infiltrates (1 of 3).
Two eyes without RR (or fellow eyes of those with RR) 
were imaged with FA, showing extrafoveal, grade 1 mac-
ular leakage in one of the eyes (1 of 2) and grade 3 macu-
lar leakage in the other eye (1 of 2). Two eyes also had 
OCT done with extrafoveal cystoid ME in one eye (1 of 
Fig. 1 Flowchart of patients with vitreoretinal lymphoma with and without macular edema. Flowchart depicting the selection of vitreoretinal 
lymphoma (VRL) patients at Mayo Clinic. Fluorescein angiography (FA), optical coherence tomography (OCT), macular edema (ME), treatment (ttx), 
intravitreal (i.v.), cataract surgery with intraocular lens implantation (IOL), pars plana vitrectomy (PPV), whole-brain radiotherapy (WBRT), chemo-
therapy (CT). The point marks the eye that developed ME during our follow-up. Arrows mark eyes without radiation retinopathy (RR)
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2) and extrafoveal diffuse ME in the other eye (1 of 2). In 
the one eye which was imaged both with FA and OCT, 
there was no discrepancy between the tests to detect dif-
fuse ME. All three eyes with RR underwent imaging with 
FA and were found to have focal diffuse grade 1 macular 
leakage. Two eyes with RR were imaged with OCT, and 
one eye showed extrafoveal diffuse ME (1 of 2), while the 
other eye (1 of 2) was negative for ME changes. Nota-
bly, the FA of this eye was positive for extrafoveal diffuse 
grade 1 ME. Therefore, there was a discrepancy between 
FA and OCT to detect ME in half eyes with RR.
Two patients (three eyes) had OCT after 1-year follow-
up. In one patient, after PPV in the left eye and intravit-
real methotrexate and rituximab injections in both eyes 
and CT, the ME persisted in the right eye (eye without 
RR) and was chronic in the left eye (eye with RR) (patient 
4). In the left eye of the other patient, without history of 
WBRT, after CT treatment as a result of CNS-L presenta-
tion 5 months after our first examination and no intraoc-
ular procedures, ME was worse (patient 2).
Review of the literature
Macular edema is the result of breakdown of the inner 
endothelial blood-retinal barrier, developing an increase 
of retinal vascular permeability, which promotes the 
accumulation of fluid inside the retinal tissue [21]. This 
vasogenic effect can be modified in a wide variety of 
pathologic or pharmacologic conditions, systemic or 
intraocular [21, 22].
Reviewing the English literature, there are a few authors 
that describe the incidence of ME in VRL [12–15] (Table 3). 
The rate varies widely from 2.46% to 66.6% of cases. 
Patients with VRL who present ME also can have other 
possible sources of ME, such as antecedents of whole-brain 
radiotherapy (WBRT), chemotherapy (CT), epiretinal 
membranes, and/or intraocular procedures [12–15, 23, 24].
Turaka et  al. [15] describes the highest percentage of 
ME being 60% (6 of 10 eyes) by FA and 66.6% (2 of 3 eyes) 
by OCT, whereas systemic lymphoma was treated with 
CT in 50% of patients, external beam radiotherapy in 
25%, and combined CT and radiation in 25%. However, 
there are no specifics described stating that patients with 
ME had any history of these conditions. In other studies, 
prior radiation or CT history is not described.
Radiation retinopathy (RR) has been described after 
radiation treatments of ocular, orbital, and intracranial 
tumors several months or years after [25–27]. Retinal 
vascular endothelial cells are damaged by radiation and 
Fig. 2 Fundus photograph, FA, and OCT showing diffuse macular edema in a patient with radiation retinopathy and a history of WBRT, CT, and PPV 
(patient 1). Diffuse macular edema in right eye due to radiation retinopathy in patient with primary VRL with a history of WBRT and chemotherapy 
and pars plana vitrectomy (patient 1). The fundus examination showed 3+ cells in the vitreous, macular edema and hard exudates nasal to the 
fovea (line with dashes), and peripheral subretinal mottling and vessels sheathing 360° (a). The FA presented extrafoveal diffuse macular edema 
grade 1 (b) and diffuse extrafoveal edema by OCT (C1, 2)
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develop retinopathy [28]. Macular edema is the earli-
est clinical presentation, followed by hard exudates, 
microaneurysm, telangiectasia, hemorrhages, neovas-
cularization, and tractional retinal detachment [29]. A 
dose >50  Gy is associated with RR development. How-
ever, there are RR cases reported with doses of <35  Gy 
[30–32]. Moreover, it has been reported that CT accom-
panying the radiation treatment can accelerate RR due 
to retinal vascular damage as happens in diabetic and 
hypertensive patients [31–33].
Saito et al. [24] describes 11.53% of ME in PVRL (3 of 
26 eyes), but history of previous intraocular procedures is 
Fig. 3 Fundus photographs, FA, and OCT of eye with radiation retinopathy and fellow eye in a patient with history of WBRT and chemotherapy 
(patient 3). Diffuse macular edema in both eyes, right eye due to radiation retinopathy, in patient with a secondary VRL with a history of WBRT and 
chemotherapy and no intraocular procedures (patient 3). The fundus examination showed cotton wool spots (long arrow) and intraretinal hemor-
rhage (short arrow) in the right eye (a1) as well as an intraretinal infiltrate superotemporal to the macula (b1a, b), which could be the cause of the 
ME of this eye (eye without signs of RR). The OCT was negative for ME in the right eye (a2) and showed an extrafoveal diffuse ME in the left eye (b2). 
However, the FA presented a diffuse ME in both eyes, grade 1 in right eye and grade 3 in left eye (a3, b3)
Table 3 Summary of bibliography
VRL vitreoretinal lymphoma, No number, PPV pars plana vitrectomy, CT chemotherapy, RT radiotherapy, ERM epiretinal membrane
Author No. patients with VRL No. eyes with VRL No. eyes with macular oedema (%) Total no. of eyes with prior treatment
Cassoux et al. [12] 44 81 2 (2.46%) 3 had PPV
Velez et al. [13] 17 31 6 (19%) 4 had cataract surgery
1 had PPV
Fardeau et al. [14] 53 ? 6 patients (11.3%) ?






25% CT + RT
Jang et al. [23] 5 5 2 (40%) 1 eye was a secondary VRL, so we assume 
that had previous CT and/or RT
Saito et al. [24] 20 26 3 (11.53%) 2 eyes had ERM
Our series 9 15 6 (40%) 5 eyes had CT + RT
4 eyes had intraocular surgery
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not specified. However, 2 of 3 eyes (1 patient) presented 
epiretinal membranes in the initial presentation; there-
fore, that could be considered a risk factor to develop 
macular oedema.
Velez et al. [13] shows 19% (6 of 31 eyes) with cystoid 
ME. However, four eyes in this study had previous cata-
ract surgery and one had pars plana vitrectomy (PPV), 
suggesting that a disruption of the anterior-posterior 
chamber interface predisposes to the development of 
inflammatory signs such as ME. Cassoux et  al. [12] 
described the lowest percentage of ME of all studies at 
a rate of 2.46% (2 of 81 eyes) by FA. In this population, 
three eyes had prior PPV, but exactly which eyes had ME 
was not clear. Thus, we cannot tell if there is any associa-
tion with prior surgery in this series.
Considering all of the risk factors for ME, the rate of 
ME in the setting of VRL is not uncommon. However, 
most of the cases are related with risk factors WBRT, CT, 
epiretinal membranes and/or intraocular surgery. Thus, it 
is difficult to determine the exact incidence of ME due to 
VRL, per se, but reflects that it possibly is an uncommon 
sign in eyes without a history of systemic or intraocular 
interventions.
Conclusions
In conclusion, although ME is observed predominantly in 
disorders of the vitreous body, it appears that ME is not 
a main characteristic of VRL. Furthermore, in cases with 
marked vitreous inflammation with sheets and clusters 
of cells without ME as well as good visual acuity, one of 
our principal differential diagnoses should be VRL. How-
ever, a meticulous systemic and intraocular history must 
be evaluated in all patients since, in patients with prior 
intervention, ME may be present.
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